What is DefiniGEN?
DefiniGEN specializes in the development of advanced iPSC disease modeling services, providing critical insights into metabolic and rare diseases. With over 13 years of operational expertise, the firm offers a comprehensive suite of solutions, including efficacy and toxicology screening, alongside sophisticated gene editing services. Their portfolio features highly specialized models for conditions such as MASLD and Wilson's Disease, which are essential for pharmaceutical and biotechnology partners aiming to improve the predictability of their drug development pipelines. By focusing on scalable, human-derived liver and metabolic models, DefiniGEN serves as a vital partner for research institutions and global life sciences organizations seeking to accelerate therapeutic breakthroughs.
How much funding has DefiniGEN raised?
DefiniGEN has raised a total of $6.1M across 2 funding rounds:
Series A
$3.8M
Private Equity
$2.3M
Series A (2014): $3.8M with participation from 24 Haymarket and Cambridge Enterprise
Private Equity (2016): $2.3M led by Cambridge Enterprise
Key Investors in DefiniGEN
24 Haymarket
A London-based private network of experienced investors and operators that provides capital and strategic support to high-potential entrepreneurial ventures.
Cambridge Enterprise
The commercialization arm of the University of Cambridge, focused on supporting the translation of academic research into impactful commercial ventures.
What's next for DefiniGEN?
With the support of its recent capital injection, DefiniGEN is well-positioned to scale its proprietary iPSC platform to meet the growing demand for predictive toxicology and efficacy screening. The company is expected to prioritize the expansion of its disease model library, further enhancing its gene editing capabilities to address complex metabolic disorders. As the pharmaceutical industry shifts toward more human-centric research methodologies, DefiniGEN's strategic focus will likely involve deepening its integration with top-tier biotech firms and expanding its footprint in the global drug discovery market. This phase of growth will be defined by the continued refinement of its high-throughput screening technologies and the pursuit of new collaborative research initiatives.
See full DefiniGEN company page
